Skip to Content
Director, Neuro-Ophthalmology Clinic, NeurologyProfessor of NeurologyProfessor of
Ophthalmology and Visual Sciences
Primary Office: 2149 RCPIowa City, IA 52242
Email: email@example.comWeb: Watch profile video
MD, Medicine, Tulane University
Residency, Neurology, Washington University in St. LouisFellowship, Neuro-ophthalmology, Harvard University
Dr. Wall's research has two arms. The first is to develop strategies of visual field testing that detect visual field defects at an earlier stage and visual field change at an earlier time. To achieve these goals, we have been studying mechanisms of perimetric variability. We have been funded for this with a VA Merit review for the past 12 years. During this time we have shown that a substantial portion of the variability of perimetry is due to the stimulus size chosen. In the process, we have developed a method of visual field testing, motion perimetry, that takes advantage of these findings to lower retest variability. We are in the fourth year of a 5 year study that follows glaucoma patients with four visual field tests to determine if larger stimuli result in earlier detection of visual field change. The second arm of the research is to study idiopathic intracranial hypertension (pseudotumor cerebri) a disease of overweight women in the childbearing years that causes headache and blindness. Our goal is to find the cause of the disease and to develop evidence-based treatment strategies. Currently all treatment decisions are based on data that is retrospective and uncontrolled. Our clinical trial has now been funded by the NIH for $16 million over 5 years. The specific aims of 1) determining if diet and acetazolamide is superior to diet alone; 2) with the help of Edwin Stone's laboratory, using a genome wide association study better understand the mechanism of idiopathic intracranial hypertension.
CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
Journal of neurology.
2015 October 1. 262(10):2271-4.
Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.
2015 September 1. 85(9):799-805.
Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results.
2015 June 16. 84(24):2449-56.
Causes and Prognosis of Visual Acuity Loss at the Time of Initial Presentation in Idiopathic Intracranial Hypertension.
Investigative ophthalmology & visual science.
2015 June 1. 56(6):3850-9.
Nordic Idiopathic Intracranial Hypertension Study Group Writing Committee ,
Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
Nordic Idiopatic Intracranial Hypertension Study Group .
The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.
Idiopathic intracranial hypertension and the idiopathic intracranial hypertension treatment trial.
Size Threshold Perimetry Performs as well as Conventional Automated Perimetry with Stimulus Sizes III, V and VI for Glaucomatous Loss.
Invest Ophthalmol Vis Sci.
The Repeatability of Mean Defect with Size III and Size V Standard Automated Perimetry.
Invest Ophthalmol Vis Sci.
The Effective Dynamic Ranges of Standard Automated Perimetry Sizes III and V and Motion and Matrix Perimetry.
Date Last Modified: 06/06/2016 -
Copyright © 2015 The University of Iowa. All Rights Reserved.